Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer

Huifang Hao, Yutaka Maeda, Takuya Fukazawa, Tomoki Yamatsuji, Munenori Takaoka, Xiao Hong Bao, Junji Matsuoka, Tatsuo Okui, Tsuyoshi Shimo, Nagio Takigawa, Yasuko Tomono, Motowo Nakajima, Iris M. Fink-Baldauf, Sandra Nelson, William Seibel, Ruben Papoian, Jeffrey A. Whitsett, Yoshio Naomoto

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Midkine (MDK) is a heparin-binding growth factor that is highly expressed in many malignant tumors, including lung cancers. MDK activates the PI3K pathway and induces anti-apoptotic activity, in turn enhancing the survival of tumors. Therefore, the inhibition of MDK is considered a potential strategy for cancer therapy. In the present study, we demonstrate a novel small molecule compound (iMDK) that targets MDK. iMDK inhibited the cell growth of MDK-positive H441 lung adenocarcinoma cells that harbor an oncogenic KRAS mutation and H520 squamous cell lung cancer cells, both of which are types of untreatable lung cancer. However, iMDK did not reduce the cell viability of MDK-negative A549 lung adenocarcinoma cells or normal human lung fibroblast (NHLF) cells indicating its specificity. iMDK suppressed the endogenous expression of MDK but not that of other growth factors such as PTN or VEGF. iMDK suppressed the growth of H441 cells by inhibiting the PI3K pathway and inducing apoptosis. Systemic administration of iMDK significantly inhibited tumor growth in a xenograft mouse model in vivo. Inhibition of MDK with iMDK provides a potential therapeutic approach for the treatment of lung cancers that are driven by MDK.

Original languageEnglish
Article numbere71093
JournalPLoS One
Volume8
Issue number8
DOIs
Publication statusPublished - Aug 16 2013

Fingerprint

lung neoplasms
Non-Small Cell Lung Carcinoma
growth factors
Intercellular Signaling Peptides and Proteins
Cells
Molecules
neoplasms
lungs
phosphatidylinositol 3-kinase
adenocarcinoma
cell growth
Lung Neoplasms
cells
therapeutics
Tumors
heparin
growth models
cell viability
fibroblasts
Phosphatidylinositol 3-Kinases

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hao, H., Maeda, Y., Fukazawa, T., Yamatsuji, T., Takaoka, M., Bao, X. H., ... Naomoto, Y. (2013). Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer. PLoS One, 8(8), [e71093]. https://doi.org/10.1371/journal.pone.0071093

Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer. / Hao, Huifang; Maeda, Yutaka; Fukazawa, Takuya; Yamatsuji, Tomoki; Takaoka, Munenori; Bao, Xiao Hong; Matsuoka, Junji; Okui, Tatsuo; Shimo, Tsuyoshi; Takigawa, Nagio; Tomono, Yasuko; Nakajima, Motowo; Fink-Baldauf, Iris M.; Nelson, Sandra; Seibel, William; Papoian, Ruben; Whitsett, Jeffrey A.; Naomoto, Yoshio.

In: PLoS One, Vol. 8, No. 8, e71093, 16.08.2013.

Research output: Contribution to journalArticle

Hao, H, Maeda, Y, Fukazawa, T, Yamatsuji, T, Takaoka, M, Bao, XH, Matsuoka, J, Okui, T, Shimo, T, Takigawa, N, Tomono, Y, Nakajima, M, Fink-Baldauf, IM, Nelson, S, Seibel, W, Papoian, R, Whitsett, JA & Naomoto, Y 2013, 'Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer', PLoS One, vol. 8, no. 8, e71093. https://doi.org/10.1371/journal.pone.0071093
Hao, Huifang ; Maeda, Yutaka ; Fukazawa, Takuya ; Yamatsuji, Tomoki ; Takaoka, Munenori ; Bao, Xiao Hong ; Matsuoka, Junji ; Okui, Tatsuo ; Shimo, Tsuyoshi ; Takigawa, Nagio ; Tomono, Yasuko ; Nakajima, Motowo ; Fink-Baldauf, Iris M. ; Nelson, Sandra ; Seibel, William ; Papoian, Ruben ; Whitsett, Jeffrey A. ; Naomoto, Yoshio. / Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer. In: PLoS One. 2013 ; Vol. 8, No. 8.
@article{a9bcf75aecd0420cad815bcba888f38a,
title = "Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer",
abstract = "Midkine (MDK) is a heparin-binding growth factor that is highly expressed in many malignant tumors, including lung cancers. MDK activates the PI3K pathway and induces anti-apoptotic activity, in turn enhancing the survival of tumors. Therefore, the inhibition of MDK is considered a potential strategy for cancer therapy. In the present study, we demonstrate a novel small molecule compound (iMDK) that targets MDK. iMDK inhibited the cell growth of MDK-positive H441 lung adenocarcinoma cells that harbor an oncogenic KRAS mutation and H520 squamous cell lung cancer cells, both of which are types of untreatable lung cancer. However, iMDK did not reduce the cell viability of MDK-negative A549 lung adenocarcinoma cells or normal human lung fibroblast (NHLF) cells indicating its specificity. iMDK suppressed the endogenous expression of MDK but not that of other growth factors such as PTN or VEGF. iMDK suppressed the growth of H441 cells by inhibiting the PI3K pathway and inducing apoptosis. Systemic administration of iMDK significantly inhibited tumor growth in a xenograft mouse model in vivo. Inhibition of MDK with iMDK provides a potential therapeutic approach for the treatment of lung cancers that are driven by MDK.",
author = "Huifang Hao and Yutaka Maeda and Takuya Fukazawa and Tomoki Yamatsuji and Munenori Takaoka and Bao, {Xiao Hong} and Junji Matsuoka and Tatsuo Okui and Tsuyoshi Shimo and Nagio Takigawa and Yasuko Tomono and Motowo Nakajima and Fink-Baldauf, {Iris M.} and Sandra Nelson and William Seibel and Ruben Papoian and Whitsett, {Jeffrey A.} and Yoshio Naomoto",
year = "2013",
month = "8",
day = "16",
doi = "10.1371/journal.pone.0071093",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer

AU - Hao, Huifang

AU - Maeda, Yutaka

AU - Fukazawa, Takuya

AU - Yamatsuji, Tomoki

AU - Takaoka, Munenori

AU - Bao, Xiao Hong

AU - Matsuoka, Junji

AU - Okui, Tatsuo

AU - Shimo, Tsuyoshi

AU - Takigawa, Nagio

AU - Tomono, Yasuko

AU - Nakajima, Motowo

AU - Fink-Baldauf, Iris M.

AU - Nelson, Sandra

AU - Seibel, William

AU - Papoian, Ruben

AU - Whitsett, Jeffrey A.

AU - Naomoto, Yoshio

PY - 2013/8/16

Y1 - 2013/8/16

N2 - Midkine (MDK) is a heparin-binding growth factor that is highly expressed in many malignant tumors, including lung cancers. MDK activates the PI3K pathway and induces anti-apoptotic activity, in turn enhancing the survival of tumors. Therefore, the inhibition of MDK is considered a potential strategy for cancer therapy. In the present study, we demonstrate a novel small molecule compound (iMDK) that targets MDK. iMDK inhibited the cell growth of MDK-positive H441 lung adenocarcinoma cells that harbor an oncogenic KRAS mutation and H520 squamous cell lung cancer cells, both of which are types of untreatable lung cancer. However, iMDK did not reduce the cell viability of MDK-negative A549 lung adenocarcinoma cells or normal human lung fibroblast (NHLF) cells indicating its specificity. iMDK suppressed the endogenous expression of MDK but not that of other growth factors such as PTN or VEGF. iMDK suppressed the growth of H441 cells by inhibiting the PI3K pathway and inducing apoptosis. Systemic administration of iMDK significantly inhibited tumor growth in a xenograft mouse model in vivo. Inhibition of MDK with iMDK provides a potential therapeutic approach for the treatment of lung cancers that are driven by MDK.

AB - Midkine (MDK) is a heparin-binding growth factor that is highly expressed in many malignant tumors, including lung cancers. MDK activates the PI3K pathway and induces anti-apoptotic activity, in turn enhancing the survival of tumors. Therefore, the inhibition of MDK is considered a potential strategy for cancer therapy. In the present study, we demonstrate a novel small molecule compound (iMDK) that targets MDK. iMDK inhibited the cell growth of MDK-positive H441 lung adenocarcinoma cells that harbor an oncogenic KRAS mutation and H520 squamous cell lung cancer cells, both of which are types of untreatable lung cancer. However, iMDK did not reduce the cell viability of MDK-negative A549 lung adenocarcinoma cells or normal human lung fibroblast (NHLF) cells indicating its specificity. iMDK suppressed the endogenous expression of MDK but not that of other growth factors such as PTN or VEGF. iMDK suppressed the growth of H441 cells by inhibiting the PI3K pathway and inducing apoptosis. Systemic administration of iMDK significantly inhibited tumor growth in a xenograft mouse model in vivo. Inhibition of MDK with iMDK provides a potential therapeutic approach for the treatment of lung cancers that are driven by MDK.

UR - http://www.scopus.com/inward/record.url?scp=84881592608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881592608&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0071093

DO - 10.1371/journal.pone.0071093

M3 - Article

C2 - 23976985

AN - SCOPUS:84881592608

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e71093

ER -